Consensus Alumis Inc.

Stocks

ALMS

US0223071020

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 12/11/2026 +03			5-day change	1st Jan Change
6.620 ^USD	+3.44%		+1.85%	-32.17%

10-09	Alumis Inc. Announces New Envudeucitinib Data From The ONWARD Phase 3 Clinical Program	CI
10-09	Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy	MT

Evolution of the Average Target: Alumis Inc.

Evolution of the Target Price: Alumis Inc.

Changes in Analyst Recommendations: Alumis Inc.

07de567bb4a28f4.rq9CAOhkVTSHDNRBK1DMrxrcrXuhHSVqdSdUWEeRx5k._OAmetE3Z3bSXaAtaGiC2Fe7mE7CSEozAW8jIT3O_6jp-yVf0SYUXNU4ow~2d60e32ccab4afeac0adf6b3f008675c

Analysts' recommendations: Alumis Inc.

09-03	Guggenheim Downgrades Alumis to Neutral From Buy	MT
09-02	Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says	MT
09-02	Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating	MT
09-02	HC Wainwright Upgrades Alumis to Buy From Neutral, Adjusts Price Target to $15 From $25	MT
05-19	Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating	MT
05-15	HC Wainwright Downgrades Alumis to Neutral From Buy	MT
03-30	Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says	MT
03-30	Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating	MT
03-11	Raymond James Initiates Alumis at Strong Buy With $46 Price Target	MT
02-25	Stifel Initiates Alumis at Buy With $44 Price Target	MT
01-21	Chardan Initiates Alumis at Buy With $37 Price Target	MT
25/07/25	Wells Fargo Initiates Alumis at Overweight With $17 Price Target	MT
15/05/25	Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating	MT
10/02/25	Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating	MT
30/01/25	Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target	MT
31/10/24	Baird Initiates Alumis at Outperform With $25 Price Target	MT
17/10/24	HC Wainwright Initiates Coverage on Alumis With Buy Rating, $30 Price Target	MT
23/07/24	Cantor Fitzgerald Initiates Alumis at Overweight	MT
23/07/24	Guggenheim Initiates Alumis at Buy With $32 Price Target	MT
23/07/24	Morgan Stanley Initiates Alumis at Overweight With $36 Price Target	MT
23/07/24	Leerink Partners Initiates Alumis at Outperform With $29 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALUMIS INC.					+386.33%
	WUXI APPTEC CO., LTD.					+34.62%
	ARGENX SE					+16.21%
	LONZA GROUP AG					+8.35%
	BEONE MEDICINES AG					+9.01%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+42.36%
	CELLTRION, INC.					+35.65%
	GENMAB A/S					+13.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.4%
	Average					+58.06%
	Weighted average by Cap.					+22.10%